LIFE Geisinger Wilkes-Barre opens May 3

Older adults in Luzerne County can get the help they need to continue living independently at home as LIFE Geisinger, a day program for seniors, opens its newest location Monday in south Wilkes-Barre.

Located at 592 S. Main St. in Wilkes-Barre, the new facility provides comprehensive health and medical care to adults age 55 and older who would otherwise be confined to a nursing home.

“LIFE Geisinger has served Luzerne County residents for several years at Geisinger South Wilkes-Barre and we are excited to be able to expand those services with a brand-new facility,” said Dr. Richard Martin, LIFE Geisinger medical director. “During this pandemic, it’s important that seniors not only get the medical care they need, but also have access to frequent social activity to enhance their quality of life. LIFE Geisinger provides participants with all that and more.”

The new 14,200-square-foot facility includes primary care services with full exam rooms, recreational space, a rehabilitation gym, bathing facilities, a laundry room and a serving kitchen. This triples the capacity of the program in Wilkes-Barre to 150 participants.

Previously, LIFE Geisinger operated a small, satellite program at Geisinger South Wilkes-Barre with 55 participants, who will transfer to the new location.

H. Joyce Morano, M.D., will serve as staff physician at the LIFE Geisinger senior center in Wilkes-Barre as well as at the center located at 2300 Adams Ave. in Scranton. At full operation, LIFE Geisinger Wilkes-Barre will have about 50 full-time employees.

For more information about LIFE Geisinger, call 570-808-4780 or visit go.geisinger.org/LIFE.

3 Benefits of Getting the COVID-19 Vaccine

By: Dr. Amit Mehta, Geisinger primary care physician

With several COVID-19 vaccines approved for use in the U.S., we have a powerful tool to help us overcome the coronavirus pandemic.

But some people have concerns about being vaccinated against COVID-19. That’s where we come in.

Common concerns around the COVID-19 vaccine include safety, speed of vaccine development and potential long-term side effects.

The FDA has certain criteria for vaccine development in place to make sure all vaccines are as safe as possible. They didn’t compromise those criteria here. Experts also continue to study the long-term effects of the COVID-19 vaccine, but early research hasn’t shown cause for concern.

Whether you’re at low or high risk of serious illness from COVID, getting vaccinated is the best way to avoid a severe or even fatal infection.

Why getting the COVID-19 vaccine is smart

Still not sure about getting the vaccine — or need help convincing a loved one? Here are the main benefits that come with it:

1. It’s your best defense against COVID-19

Illness from COVID-19 can be serious and life-threatening for some people. And there’s no way to know for sure how it may affect you. Even if you have a mild case of COVID, you can still spread it to a loved one who may get really sick.

All COVID-19 vaccines available in the U.S. have been shown to be highly effective at preventing illness from COVID-19. And based on early data, getting a vaccine helps keep you from getting seriously ill if you do get COVID-19.

While it’s normal to experience some side effects right after receiving the vaccine — like a fever, headache or body aches — these are all signs that your body is building immunity to the virus. None of the vaccines can give you COVID-19.

2. It’s a safer way to achieve immunity from COVID-19

Even if you’ve already had COVID-19, you should still get vaccinated — but be sure to wait at least 10 days after your symptoms started and 20 days if you were hospitalized from COVID-19.

While having COVID will leave you with naturally produced antibodies, we still don’t know the level of or how long this immunity lasts. We do know that it varies and decreases over time, and that getting a COVID-19 vaccine will likely give you additional immunity.

And again, it’s just not worth risking a serious or fatal COVID-19 infection.

3. It can help us end the pandemic

Now over a year into the COVID-19 pandemic, many of us are ready to leave our homes without masks, spend time with friends and loved ones and maybe even travel.

The COVID-19 vaccine can help us get there.

While masking, handwashing and physical distancing are proven to help reduce exposure to and the spread of COVID-19, they aren’t enough to end the pandemic. Vaccines will help us build up immunity to COVID-19, so our bodies can fight off the virus if we’re exposed.

And per CDC guidelines, those who are fully vaccinated, meaning it’s been at least 2 weeks since the last required dose, can even return to some pre-pandemic activities.

We’re still learning how the current vaccines will affect the spread of COVID-19. Until we know more, everyone — vaccinated or not — should continue masking, handwashing and physical distancing in public places.

Eventually, as more people are vaccinated, we can loosen preventive measures as federal and state guidelines allow.

Get reliable information on COVID-19 vaccines

There’s a lot of information out there about the COVID-19 vaccines — and some of it may be misleading.

If you have questions about the COVID-19 vaccine, your doctor is your best resource. They can give you advice that’s tailored to you and your medical history.

If you’d like to do some research on your own, the CDC is a trusted source for vaccine information that’s based on facts.

Based on the data we have from Phase 3 clinical trials and the millions of Americans now vaccinated, we feel confident that the available COVID-19 vaccines are safe and effective. I have personally received the COVID-19 vaccine and advise my patients and members of the community to do the same.

Geisinger Data Shows COVID-19 Vaccine Proving Effective

With more than a quarter million doses administered, and eligibility expanded to everyone 16 and older, Geisinger’s data indicates the COVID-19 vaccine is proving effective among those vaccinated in earlier phases. To date, Geisinger has administered 266,000 vaccine doses.

Based on Pennsylvania Department of Health guidelines in December 2020, Geisinger employees were among the first groups to be vaccinated. As a result, the weekly average of new positive COVID-19 tests among employees has remained in the single digits since early February, down from the mid-30s in early December. Since employee vaccinations began in mid-December, we saw positive testing rates among employees plummet through January and stay consistently low as more employees received the vaccine (see figure 1).

The trended COVID-19 vaccinations of Geisinger employees versus the seven-day average of COVID-19 positive employee tests.

Similarly, the average number of COVID-19 admissions for those age 65 and older has also decreased significantly as vaccines have been rolled out to that age group starting in mid- January.

“The science — and our data — clearly demonstrates these vaccines are proving effective in helping prevent illness, hospitalizations and death,” said Jaewon Ryu, JD, MD, Geisinger president and chief executive officer. “If we are looking to put this pandemic behind us and return to a sense of normalcy, the vaccine is a great way to get there.”

While the vaccine is proving effective for many who have received it, a worrying trend is emerging across Geisinger’s communities. For the second week in a row, the majority of those being hospitalized for COVID-19 are younger than 65, with a growing number between age 25 and 49.

“What we don’t want is this increase of hospital admissions among younger people to accelerate. The vaccine can keep that from happening,” Ryu said. “Masking, social distancing and other mitigation efforts have helped us as well so far, but the best way we can win this fight is with the vaccine. It will help us get out in front of this virus and its potential mutations that threaten our ability to get our communities back to normal.”

Vaccine appointments remain available at Geisinger’s four vaccine centers in central and northeastern Pennsylvania. You can self-schedule a vaccine appointment through myGeisinger or by calling 570-284-3657. It still remains critical for everyone – vaccinated or not – to keep wearing a mask, physical distancing, and practicing good hand hygiene to stop the virus’ spread. For the latest information on the COVID vaccine, visit geisinger.org/COVIDVax.

Geisinger Hosts Free Community Shred Day Events

In observance of Earth Day, Geisinger is hosting free Community Shred Day events at several locations. Community members can bring their confidential personal and financial documents, such as bank statements, credit card bills and tax forms, to be securely shredded on-site and recycled.

Limit of three boxes of paper per person. Paper only please — do not put other waste into bins.

Join us for a Shred Day event near you:

  • Thursday, April 22, 7 – 11 a.m. at Geisinger Mt. Pleasant, 531 Mt. Pleasant Drive, Scranton
  • Friday, April 30, 7 – 11 a.m.; Monday, May 3, noon – 4 p.m. at Geisinger Orthopaedics Institute parking lot, 1175 East Mountain Blvd., Wilkes-Barre

For more information, call 570-271-6030.

Scranton Chamber Participates in Geisinger Meals in Spring

Program supports local restaurants hit hard by pandemic

Geisinger partnered with eight local chambers of commerce to launch Meals in Spring and give back to the restaurants in the community hit hard by the pandemic.

As part of the program, more than 23,000 Geisinger employees can redeem a $10 meal voucher at more than 250 participating restaurants across 12 counties through June 30.

“Our local chambers of commerce were among the first organizations that came to us during the early days of the pandemic offering help,” said John Grabusky, senior director of community relations. “They collected N95 masks and gloves, organized sewing groups for homemade masks and they were behind many donations of pizzas, sandwiches, coffees and snacks that started to flow into our facilities. Now, it’s our turn to help them by supporting our local restaurants with Meals in Spring.”

Studies have shown that for every $100 spent at locally owned businesses, $68 stays within the community. By patronizing local restaurants, Geisinger employees are contributing to the local economy, which benefits their friends, neighbors, school districts and nonprofit organizations in their communities.

Participating chambers of commerce include Columbia Montour Chamber of Commerce, Greater Wyoming Chamber of Commerce, Greater Scranton Chamber of Commerce, Schuylkill Chamber of Commerce, Greater Susquehanna Valley Chamber of Commerce, Juniata River Valley Chamber of Commerce, Clinton County Economic Partnership & Visitors Bureau, and Williamsport/Lycoming Chamber of Commerce.

FDA Grants Breakthrough Device Designation to Tempus in Collaboration With Geisinger

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.

The platform was designated as a Breakthrough Device for use with patients 40 years of age and older, without pre-existing or concurrent AFib or atrial flutter, and who are at elevated risk of stroke based on a commonly used clinical stroke risk assessment tool (i.e., CHA₂DS₂-VASc score of ≥4). The device analyzes the results of a 12-lead ECG administered as part of routine care to provide clinicians with insight into a patient’s risk of future atrial fibrillation and/or atrial flutter events. When interpreted in conjunction with other available clinical information this can support clinicians in pursuing early and proactive diagnoses of AFib and atrial flutter with the goal of enabling improved clinical management of these conditions and their associated health risks.

AFib, which is a leading cause of stroke, is frequently unrecognized and untreated. Currently, there are no available devices to help physicians identify asymptomatic patients without a known history of cardiac arrhythmia who are at increased risk of future AFib, which carries other health risks including stroke and death. The Tempus ECG Analysis Platform is tackling that challenge by analyzing results of a widely used clinical test, the 12-lead ECG, with software that identifies patients at increased risk of developing AFib or atrial flutter within the next 12 months.

A team of Geisinger and Tempus scientists and clinicians recently published a related study in Circulation, which showed that artificial intelligence can predict risk of new AFib and AFib-related stroke. For this research study, the combined team of data scientists and medical researchers used 1.6 million ECGs to train a deep neural network to predict, among people without a previous history of AFib, who would develop it within the next 12 months. In people with no history of AFib that went on to have an AFib-related stroke, nearly two thirds would have been predicted to be at high-risk before the stroke.

“In granting our request for Breakthrough Device designation, the FDA is helping bring the power of artificial intelligence to patients, with new, smarter tools that can support clinicians in predicting future clinical events,” said Joel Dudley, Ph.D., Chief Scientific Officer of Tempus. “Every year, hundreds of millions of ECGs are performed in the U.S. to detect cardiac abnormalities as part of routine clinical care. We are making ECGs smarter so that they can also identify the risk of future clinical events of interest, such as AFib, thus enabling clinicians to act earlier in the course of disease and improve patient outcomes.”

“Much of what we do as clinicians relies on predicting the future. Geisinger and Tempus are working together to make smarter, more accurate predictions about future clinical events,” said Brandon Fornwalt, MD, Ph.D., Chair of Geisinger’s Department of Translational Data Science and Informatics. “This is ultimately about helping patients and fulfilling the promise of precision health by supporting clinical decision making with additional patient-specific information, and we are excited that the FDA recognizes the importance of this work.” The FDA’s Breakthrough Device Program was established to accelerate the availability of transformative medical devices to patients and healthcare providers by speeding up their development, assessment and review, while preserving the statutory standards for premarket review and authorization. Designation is awarded to innovative devices that provide more effective diagnosis or treatment of life-threatening conditions and that offer significant advantages over the existing standard of care, where no approved or cleared alternatives exist, and where early device availability is in patients’ best interests.

Geisinger Launches Innovative, Non-Invasive Treatment Option for Patients With Knee Pain

Geisinger, in partnership with AposHealth, today announced that a new non-invasive, drug-free treatment for patients suffering knee pain from osteoarthritis will be available to Geisinger Health Plan’s commercial members in Pennsylvania starting on April 1.  AposHealth treatment is available exclusively at Geisinger in Central and Northeast Pennsylvania.

Developed by experts in orthopedics and sports medicine, the AposHealth device is approved by the U.S. Food and Drug Administration to help temporarily reduce knee pain and improve lower extremity function.

The AposHealth program is a year-long, at-home treatment that requires patients to wear a personalized device for approximately one hour a day during normal daily activities.  Supported by more than 60 clinical studies, including recent research published in The Journal of the American Medical Association (JAMA), patients using the AposHealth system have experienced significant improvements in temporary pain relief, function and gait patterns.

“Providing personalized treatments for individual conditions is a tenet of Geisinger’s approach to musculoskeletal care,” said Michael Suk, MD, JD, Chief Physician Officer, System Services and Chair of the Musculoskeletal Institute at Geisinger. “AposHealth’s at-home treatment is perfectly aligned with our way of thinking of managing total health. Embracing new technologies and treatments allows us to reimagine the care pathway for knee osteoarthritis.”

“We are excited to be part of the innovative approach to treating knee pain taken by Geisinger, a Center of Excellence for Knee Replacements. This partnership brings a convenient, clinically proven knee osteoarthritis treatment option to patients and provides clinicians with an alternative non-invasive option,” added Cliff Bleustein, MD President and CEO of AposHealth®.

The AposHealthtreatment is currently available to Geisinger Health Plan’s commercial members in selected Geisinger locations in Danville, Wilkes-Barre and Scranton. Throughout 2021 Geisinger will be exploring opportunities to make this treatment available to more Geisinger patients across the it’s footprint in Central Pennsylvania. Please call 800-275-6401 to schedule an appointment.

Geisinger Partners With Acadia Healthcare to Expand Behavioral Health Services

Geisinger and Acadia Healthcare Company have formed a joint venture to address the urgent need for expanded, high-quality inpatient behavioral health services in central and northeastern Pennsylvania. As part of the joint venture, two new freestanding inpatient behavioral health facilities will be constructed in Moosic and Danville with plans to serve adult and pediatric patients beginning in 2022 and 2023 respectively.

Geisinger, which serves more than 1 million people across 45 counties in Pennsylvania, has partnered with Acadia Healthcare, the nation’s largest stand-alone behavioral healthcare company, to establish these new 96-bed, 73,000-square-foot facilities. Geisinger chose Acadia Healthcare, as its partner based on their shared commitment to quality care, strong clinical outcomes, and successful track record of collaborating with numerous premier health systems. Geisinger and Acadia will be investing a combined close to $80 million into these two facilities that together are expected to create approximately 200 new jobs by 2024.

“At Geisinger, we are setting out to make better health easier for the communities we serve,” said Jaewon Ryu, MD, JD, Geisinger’s president and CEO. “This joint venture was a natural fit based on a shared commitment to identifying behavioral health needs in the community and partnering to bring world-class care close to home for everyone who needs it in central and northeastern Pennsylvania.”

Both the Danville and Moosic locations are easily accessible from the entire central and northeastern Pennsylvania regions, and are near Geisinger hospitals in Danville, Scranton and Plains Township. Construction is scheduled to begin in Moosic in Fall 2021 and in Danville in 2022. The partnership will provide an opportunity for Geisinger to consolidate inpatient behavioral health programs from Geisinger Medical Center, Geisinger Bloomsburg Hospital and Geisinger Community Medical Center into these new facilities, which will allow an opportunity for these vacated units to be repurposed for additional capacity, including expanded private room availability.

“Acadia is proud to be partnering with a leading health system like Geisinger to provide these life-saving services to individuals and families throughout central and northeast Pennsylvania,” said Debbie Osteen, Chief Executive Officer of Acadia Healthcare. “We look forward to collaborating with Geisinger to create these two state-of-the-art, patient-centered facilities that will provide hope and healing for those in need. The increased bed availability and freestanding structures will enable us to care for more patients who require these critical services and help meet the growing need for inpatient behavioral healthcare in these communities.”

A recently released 2020 Mental Health America Report estimates that 47 million Americans now struggle with mental health challenges, an increase of 4 million people since the 2018 report, which mirrors trends locally in central and northeastern Pennsylvania. Upon completion, the two new inpatient behavioral health facilities will address current and future demand for adult, pediatric and adolescent patients who struggle with acute symptoms of mental health disorders such as anxiety, depression, bipolar disorder, psychosis, and posttraumatic stress disorder (PTSD). This vast array of acute behavioral health services provides a level of care previously not seen in central and northeastern Pennsylvania, especially for children and adolescents.

Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.

Geisinger South Wilkes-Barre Opens New Cardiology Clinic

Geisinger has opened a new cardiology clinic on the campus of Geisinger South Wilkes-Barre to make heart-care services more accessible to the community and better health easier for patients in northeastern Pennsylvania.

The newly renovated space at 50 Roosevelt Terrace offers pediatric and adult cardiology services, providing care for adult patients with congenital heart disease, and featuring noninvasive diagnostics like echocardiography and electrocardiography. Pediatric spaces were specifically designed to calm the youngest congenital-heart patients.

Staffed daily with cardiologists, advanced practitioners, sonographers and technicians to accommodate both pediatric and adult patients, the refinished clinic features a new echocardiography bed, electrocardiography (ECG or EKG) machine, and high-end blanketwarming
cabinet.

“We know patients have wanted a cardiology practice to come back to the South Wilkes-Barre community for some time, and we wanted to provide that service again,” said Kelly Austin, RN,
operations manager for the clinic. “This practice will increase appointments available to cardiology patients in Luzerne County and bring cardiology services closer to home for patients in or near South Wilkes-Barre.”

Pediatric cardiologist Dr. Karen Lurito will lead pediatric cardiology services at the clinic, and she is passionate about expanding heart care in the northeast.

“In one place, you get a full spectrum of care. We have the ability to treat children with cardiovascular disease and continue that specialized care as they mature,” Lurito said, noting the importance of lifelong care for the growing number of patients who now live longer with congenital heart disease due to advancements in treatment.

Patients who need additional heart-care services can take advantage of the robust cardiology and congenital heart disease programs at Geisinger. For example, services in interventional cardiology, electrophysiology, cardiac surgery, pediatric stress testing and metabolic stress testing are all available in the northeast at Geisinger Wyoming Valley Medical Center. And pediatric and congenital heart surgery services are offered at Geisinger Medical Center in Danville.

Systemwide, the congenital heart team has been strengthened recently with the addition of a surgeon with 30 years of experience to lead pediatric and adult congenital heart surgery and a certified registered nurse practitioner well-versed in building adult congenital heart disease programs. The team also features cardiologists who have achieved Adult Congenital Heart Disease board certification and can care for patients throughout their lives.

Care even extends to the maternal and fetal medicine clinic, where pediatric cardiologists will do echocardiography on fetuses.

“We will care for you from your prenatal days all the way through adulthood,” Lurito said.

Geisinger Celebrates 40th Anniversary of Child Life Department

The Child Life Department at Geisinger is celebrating its 40th anniversary this month coinciding with Child Life Month. It is a time to celebrate child life specialists at Geisinger Janet Weis Children’s Hospital (JWCH) who support pediatric patients and their families through play, education and emotional support.

“Child Life’s presence at Geisinger has been long standing and incredibly impactful,” said Dr. Frank Maffei, MD, Chair of the Department of Pediatrics. “Their 40 years at Geisinger predates the construction of our JWCH and the services they provide to our children are indeed foundational and essential.”

In the program’s early days, specialists focused on playroom activities that encouraged socialization and self-expression, normalizing the hospital environment, providing support for patients and family members of chronically ill patients, supervising volunteers in the inpatient setting and event planning to gather donations for funding.

The team also offers medical play to work through feelings and understanding of medical experiences, preparation for tests and procedures, pet therapy, and serve as liaison to the CSIU Hospital School Teacher Program so children don’t fall behind in their academics while hospitalized and more.

15-year-old patient, Leah Williams and her family have had a positive experience with a child life specialist at JWCH. Leah was officially diagnosed with “ALG 13 mutation” in 2014. This condition is a rare disorder and disease-causing variants in ALG13 have been reported in fewer than 20 individuals. Leah’s diagnosis means that she has a seizure disorder, a severe developmental delay, and hypotonia.

“Child Life has helped Leah cope and feel comfortable while being at the hospital. Our child life specialist Rose Lauck noticed that Leah responds well to physical touch and enjoys having her arms, feet, and hair rubbed. Rose also makes sure there are things for Leah to look at or listen too while being seen. When it’s time for Leah to have a procedure, she stays with us and provides continuous reassurance. The support has been tremendous, and we are grateful for it,” said Krista Williams, Leah’s mom.

Today, the Child Life team has grown to 12 certified child life specialists who support patients admitted to the JWCH inpatient setting, both at Geisinger Medical Center and Geisinger Wyoming Valley, and children visiting various pediatric outpatient subspeciality clinics. This includes hematology and oncology, gastroenterology, cystic fibrosis and orthopedics clinics, same day surgery, sedation services and the emergency department.

“The 40th anniversary of our Child Life Department is a celebration of our past, present and future. The continued growth of our department is a result of both the hard work the team has invested over the years and the strong working relationships they have built with members of the multidisciplinary team,” said Rebecca Drumheller, Geisinger’s Child Life Program manager. “Our programming continues to expand as these creative, flexible, out-of-the-box thinkers take the initiative to improve upon the services we provide for our patients and families,” she added.

To learn more about Geisinger’s Child Life services, special events or how to make a donation, click here.